Life Extension Spring Clearance Sale

Atherosclerosis and Cardiovascular Disease References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. American Heart Association. Heart Disease and Stroke Statistics, 2010. Available at: http://www.americanheart.org/downloadable/heart/1265665152970DS-3241%20HeartStrokeUpdate_2010.pdf
  2. Matsuura E et al. Oxidation of LDL and its clinical implication. Autoimmun Rev. 2008 Jul;7(7):558-66.
  3. Rifai N, Ridker PM. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem. 2001;47(3):403–11.
  4. Rifai N. C-reactive protein and coronary heart disease: Diagnostic and therapeutic implications for primary prevention. Cardiovasc Toxicol. 2001;1(2):153–7.
  5. Di Napoli M, Papa F, et al. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32(1):133–8.
  6. Wan JB et al. Endogenously Decreasing Tissue n-6/n-3 Fatty Acid Ratio Reduces Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice by Inhibiting Systemic and Vascular Inflammation. Arterioscler Thromb Vasc Biol. 2010 Aug 12.
  7. Beckman JA, Creager MA, et al. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–81.
  8. Bjørnholt JV et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care January 1999 vol. 22 no. 1 45-49.
  9. Bonora E et al. Insulin Resistance as Estimated by Homeostasis Model Assessment Predicts Incident Symptomatic Cardiovascular Disease in Caucasian Subjects From the General Population The Bruneck Study. Diabetes Care February 2007 vol. 30 no. 2 318-324
  10. Riba R, Nicolaou A, et al. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis. 2004;175(1):69–75.
  11. Guilland JC, Favier A, et al. [Hyperhomocysteinemia: An independent risk factor or a simple marker of vascular disease? 2. Epidemiological data]. Pathol Biol (Paris). 2003;51(2):111–21.
  12. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: Effects of vitamins. Cardiovasc Drugs Ther. 2002;16(5):391–9.
  13. Koenig W. Fibrinogen and coronary risk. Curr Cardiol Rep. 1999;1(2):112–8.
  14. Massberg S, Enders G, et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood. 1999;94(11):3829–38.
  15. Wilhelmsen L, Svardsudd K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311(8):501–5.
  16. Packard CJ, O’Reilly DS, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343(16):1148–55.
  17. Danesh J et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005 Oct 12;294(14):1799-809.
  18. 17a.  Bots ML, Elwood PC, et al. Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health. 2002;56 Suppl 1:i14-18.

  19. Dobnig H et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008 Jun 23;168(12):1340-9.
  20. Adams J and Pepping J. Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am J Health Syst Pharm. 2005 Aug 1;62(15):1574-81.
  21. Beulens JW et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009 Apr;203(2):489-93.
  22. Schurgers LJ, Spronk HM, Soute BA, et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007 Apr;109(7):2823-31.
  23. Morishita M et al. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. J Rheumatol. 2008 Mar;35(3):407-13.
  24. Geleijnse JM et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004 Nov;134(11):3100-5.
  25. Nouso K et al. Regression of hepatocellular carcinoma during vitamin K administration. World J Gastroenterol. 2005 Nov 14;11(42):6722-4.
  26. Lin C et al. Vitamin K3 triggers human leukemia cell death through hydrogen peroxide generation and histone hyperacetylation. Pharmazie. 2005 Oct;60(10):765-71.
  27. Braam LA et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost. 2004 Feb;91(2):373-80.
  28. Berkner KL et al. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost. 2004 Dec;2(12):2118-32.
  29. Gunther KE et al. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res. 2004;113(3-4):205-9.
  30. Wranicz JK et al. The relationship between sex hormones and lipid profile in men with coronary artery disease. Int J Cardiol. 2005 May 11;101(1):105-10.
  31. Abbott RD et al. Serum estradiol and risk of stroke in elderly men. Neurology. 2007 Feb 20;68(8):563-8.
  32. Tivesten A et al. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. J Clin Endocrinol Metab. 2006 Nov;91(11):4433-7.
  33. Dunajska K et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male. 2004 Sep;7(3):197-204.
  34. Stork S et al. Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J Intern Med. 2008 Sep;264(3):245-53.
  35. Zegura B et al. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause. 2006 Jul-Aug;13(4):643-50.
  36. Jankowska EA, Rozentryt P, Ponikowska B. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009 May 13;301(18):1892-901.
  37. Langsjoen PH and LAngsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9(2-4):273-84.
  38. Yavuz BB et al. Advanced age is associated with endothelial dysfunction in healthy elderly subjects. Gerontology. 2008;54(3):153-6.
  39. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000 Nov 10;87(10):840-4.
  40. Nitenberg A. [Hypertension, endothelial dysfunction and cardiovascular risk] Arch Mal Coeur Vaiss. 2006 Oct;99(10):915-21.
  41. Kulkarni KR et al. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J Lipid Res. 1995 Nov;36(11):2291-302.
  42. Ensign W et al. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem. 2006 Sep;52(9):1722-7.
  43. Kulkarni KR et al. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. J Lipid Res. 1997 Nov;38(11):2353-64.
  44. Brook RD et al. Usefulness of low-density lipoprotein particle size measurement in cardiovascular disease prevention. Clin Cardiol. 2005 Nov;28(11):534-7.
  45. Kulkarni KR et al. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 2006 Dec;26(4):787-802.
  46. Miller M, Dobs A, Yuan Z, Battisti WP, Palmisano J. The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. Curr Med Res Opin. 2006 Feb;22(2):343-50.
  47. Robinson JG and Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006 Aug 21;98(4A):39i-49i.
  48. Schmidt EB et al. Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis. 2008 Jan;196(1):420-4.
  49. Hjerkinn EM et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil. 2006 Jun;13(3):325-33.
  50. Schiano V et al. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr. 2008 Apr;27(2):241-7.
  51. Mindrescu C et al. Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia. Vasc Health Risk Manag. 2008;4(6):1439-47.
  52. Kaiser KP, Feinendegen LE. Planar scintigraphy versus PET in measuring fatty acid metabolism of the heart. Herz. 1987 Feb;12(1):41–50.
  53. Wiseman LR, Brogden RN. Propionyl-L-carnitine. Drugs Aging. 1998 Mar;12(3):243–8; discussion 249–50.
  54. Signorelli SS et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney Blood Press Res. 2006;29(2):100-7.
  55. Spagnoli LG, Orlandi A, et al. Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits. Atherosclerosis. 1995 Apr 7;114(1):29–44.
  56. Bueno R, Alvarez de Sotomayor M, et al. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: Different participation of NO and COX-products. Life Sci. 2005 Sep 9;77(17):2082–97.
  57. Cockcraft JR. Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens. 2005 Dec;18(12 Pt 2):177S–83S. Review.
  58. Oka RK, Szuba A, Giacomini JC, et al. A pilot study of L-arginine supplementation on functional capacity in peripheral artery disease. Vasc Med. 2005 Nov;10(4):265-74.
  59. Yin WH, Chen JW, et al. L-arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. Clin Nutr. 2005 Dec;24(6):988–97.
  60. Kalen A et al. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989 Jul;24(7):579-84.
  61. 59a.  Folkers K, Wolaniuk J, Simonsen R, et al. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985 Jul;82(13):4513-6.

  62. Thomas SR et al. Coantioxidants make alpha-tocopherol an efficient antioxidant for low-density lipoprotein. Am J Clin Nutr. 1995 Dec;62(6 Suppl):1357S-1364S.
  63. Shargorodsky M et al. Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. Nutr Metab (Lond). 2010 Jul 6;7:55.
  64. Graham D et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009 Aug;54(2):322-8.
  65. Jakubowski H, Ambrosius WT, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett. 2001 Feb 23;491(1-2):35-9.
  66. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON-1) deficiency is associated with increased macrophage oxidative stress: studies in PON-1-knockout mice. Free Radic Biol Med. 2003 Mar 15;34(6):774-84.
  67. Leus FR, Wittekoek ME, Prins J, Kastelein JJ, Voorbij HA. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis. 2000 Apr;149(2):371-7.
  68. Sapian-Raczkowska B, Rabczyński M, Adamiec R. [Paraoxonase—important enzyme of the lipid metabolism and potential ally in the antiatherosclerotic treatment]. Pol Merkur Lekarski. 2010;29(173):325-7. [Article in Polish]
  69. Ikeda Y, Suehiro T, Itahara T, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol. 2007 Jun;67(6):358-65.
  70. Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr. 2000 May;71(5):1062-76.
  71. van Himbergen TM, van Tits LJ, Roest M, Stalenhoef AF. The story of PON-1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med. 2006 Feb;64(2):34-8.
  72. Packer L, Kraemer K, et al. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001;17(10):888–95.
  73. Lee WJ, Lee IK, et al. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler Thromb Vasc Biol. 2005a Dec;25(12):2488–94.
  74. Sola S, Mir MQ, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005 Jan 25;111(3):343–8.
  75. Mosca L, Marcellini S, et al. Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. Biochem Pharmacol. 2002;63(7):1305–14.
  76. Orekhov AN, Tertov VV, et al. Direct anti-atherosclerosis-related effects of garlic. Ann Med. 1995 Feb;27(1):63–5.
  77. Williams MJ, Sutherland WH, et al. Aged garlic extract improves endothelial function in men with coronary artery disease. Phytother Res. 2005 Apr;19(4):314–9.
  78. Koscielny J, Klussendorf D, et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis. 1999 May;144(1):237–49.
  79. Kudolo GB, Wang W, et al. Oral ingestion of Ginkgo biloba extract reduces thiobarbituric acid reacting (TBAR) substances in washed platelets of healthy subjects. J Herb Pharmacother. 2003;3(4):1–15.
  80. Ou HC et al. Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol. 2009 May;106(5):1674-85.
  81. Pierre SV et al. The standardized Ginkgo biloba extract Egb-761 protects vascular endothelium exposed to oxidized low density lipoproteins. Cell Mol Biol (Noisy-le-grand). 2008 Oct 26;54 Suppl:OL1032-42.
  82. Tsai JY et al. EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res. 2010 Dec 1;88(3):415-23.
  83. Rodriguez et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis. 2007 Jun;192(2):438-44.
  84. Liu F et al. Inhibitory effect of Ginkgo biloba extract on hyperhomocysteinemia-induced intimal thickening in rabbit abdominal aorta after balloon injury. Phytother Res. 2008 Apr;22(4):506-10.
  85. Balestrieri ML, Schiano C, Felice F, et al. Effect of low doses of red wine and pure resveratrol on circulating endothelial progenitor cells. J Biochem (Tokyo). 2007 Nov 4.
  86. Ungvari Z, Orosz Z, Rivera A, et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2417-24.
  87. Wang XB, Huang J, Zou JG, et al. Effects of resveratrol on number and activity of endothelial progenitor cells from human peripheral blood. Clin Exp Pharmacol Physiol. 2007 Nov;34(11):1109-15.
  88. Ballard VL, Edelberg JM. Targets for regulating angiogenesis in the ageing endothelium. Expert Opin Ther Targets. 2007 Nov;11(11):1385-99.
  89. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 5;295(13):1556-65.
  90. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002 Oct 15;106(16):2055-60.
  91. Crouse JR, III, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007 Mar 28;297(12):1344-53.
  92. Cloarec M, Caillard P, Provost JC, et al. GliSODin, a vegetal sod with gliadin, as preventative agent vs. atherosclerosis, as confirmed with carotid ultrasound-B imaging. Allerg Immunol.(Paris). 2007 Feb;39(2):45-50.
  93. Opie LH and Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J. 2007 Jul;28(14):1683-93.
  94. Chen WP et al. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur J Pharmacol. 2007 Jan 12;554(2-3):196-204.
  95. Kuhlman DR, Schaefer CA, et al. Quercetin-induced induction of the NO/cGMP pathway depends on Ca2+-activated K+ channel-induced hyperpolarization-mediated Ca2+-entry into cultured human endothelial cells. Planta Med. 2005 Jun;71(6):520–4.
  96. Machha A, Mustafa MR. Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta. J Cardiovasc Pharmacol. 2005 Jul;46(1):36–40.
  97. Reiterer G, Toborek M, et al. Quercetin protects against linoleic acid-induced porcine endothelial cell dysfunction. J Nutr. 2004 Apr;134(4):771–5.
  98. Lee W, Min WK, et al. Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. Clin Biochem. 2005b Jan;38(1):84–7.
  99. Sano J, Inami S, et al. Effects of green tea intake on the development of coronary artery disease. Circ J. 2004 Jul;68(7):665–70.
  100. Sasazuki S, Kodama H, et al. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Ann Epidemiol. 2000 Aug;10(6):401–8.
  101. Dietrich M, Block G, et al. Antioxidant supplementation decreases lipid peroxidation biomarker F(2)-isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev. 2002;11(1):7–13.
  102. Fang JC, Kinlay S, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: A randomised trial. Lancet. 2002;359(9312):1108–13.
  103. Antoniades C, Tousoulis D, et al. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: The effects of vitamin C. Diabet Med. 2004 Jun;21(6):552–8.
  104. Jie KSG, et al. Vitamin K status and bone mass in women with and without aortic atherosclerosis: A population based study. Calcif Tiff Int. 1996;59:352–6.
  105. Howe AM, Webster WS. Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol. 2000 Feb;81(1):51–6.
  106. Geleijnse JM et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004 Nov;134(11):3100-5.
  107. Beulens JW et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009 Apr;203(2):489-93.
  108. Munteanu A, Zingg JM, et al. Anti-atherosclerotic effects of vitamin E—myth or reality? J Cell Mol Med. 2004;8(1):59–76.
  109. Harris A, Devaraj S, et al. Oxidative stress, alpha-tocopherol therapy, and atherosclerosis. Curr Atheroscler Rep. 2002;4(5):373–80.
  110. Wu D, Liu L, Meydani M, et al. Effect of vitamin E on prostacyclin (PGI2) and prostaglandin (PG) E2 production by human aorta endothelial cells: mechanism of action. Ann N Y Acad Sci. 2004 Dec;1031:425-7.
  111. Ohrvall M, Sundlof G, Vessby B. Gamma, but not alpha, tocopherol levels in serum are reduced in coronary heart disease patients. J Intern Med. 1996 Feb;239(2):111-7.
  112. Kontush A, Spranger T, Reich A, Baum K, Beisiegel U. Lipophilic antioxidants in blood plasma as markers of atherosclerosis: the role of alpha-carotene and gamma-tocopherol. Atherosclerosis. 1999 May;144(1):117-22.
  113. Ohrvall M, Tengblad S, Vessby B. Tocopherol concentrations in adipose tissue. Relationships of tocopherol concentrations and fatty acid composition in serum in a reference population of Swedish men and women. Eur J Clin Nutr. 1994 Mar;48(3):212-8.
  114. Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996 May 2;334(18):1156-62.
  115. Saldeen T, Li D, Mehta JL. Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol. 1999 Oct;34(4):1208-15.
  116. Li D, Saldeen T, Romeo F, Mehta JL. Relative effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation and superoxide dismutase and nitric oxide synthase activity and protein expression in rats. J Cardiovasc Pharmacol Ther. 1999 Oct;4(4):219-26.
  117. Carlson LA et al. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005 Aug;258(2):94–114.
  118. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec; 8(6):1245-55.
  119. Magen E et al. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens. 2005 Sep;19(9):667-73.
  120. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of athero-thrombosis. Am J Cardiovasc Drugs. 2005;5(6):399-408.
  121. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 Mar 5;105(9):1135-43.
  122. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003 Sep 22;163(17):2006-10.
  123. American Heart Association; 2005 meeting. Available at http://cme.medscape.com/viewcollection/4739
  124. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006 Jan 18;295(3):306-13.
  125. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004 Aug;90(8):871-6.
  126. Akishita M et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007 Nov;30(11):1029-34.
  127. Malkin CJ et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010 Nov;96(22):1821-5.
  128. Militaru C et al. Serum testosterone and short-term mortality in men with acute myocardial infarction. Cardiol J. 2010;17(3):249-53.
  129. Turhan S et al. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis. 2007 May;18(3):159-62.
  130. Fogari R, Malacco E, Preti P, et al. Plasma testosterone in isolated systolic hypertension. Hypertension. 2003 Oct;42(4). Epub 2003 Sep 15.
  131. Khaw KT et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007 Dec 4;116(23):2694-701.
  132. Sievers C et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients.
  133. Sondergaard HP, Hansson LO, et al. The inflammatory markers C-reactive protein and serum amyloid A in refugees with and without posttraumatic stress disorder. Clin Chim Acta. 2004;342(1-2):93–8.
  134. Hak AE, Witteman JC, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam study. J Clin Endocrinol Metab. 2002;87(8):3632–9.
  135. Yoshida S et al. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. 2010 Sep;212(1):310-5.
  136. Simoncini T, Mannella P, et al. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology. 2003;144(8):3449–55.
  137. Register TC et al. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol. 1998 Jul;18(7):1164-71.
  138. Levine RL et al. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996 Nov 1;94(9):2221-7.
  139. Morey AK et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997 Aug;138(8):3330-9.
  140. Houser SL et al. Serum lipids and arterial plaque load are altered independently with high-dose progesterone in hypercholesterolemic male rabbits. Cardiovasc Pathol. 2000 Nov-Dec;9(6):317-22.
  141. Adams MR et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):217-21.
  142. Adams MR et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990 Nov-Dec;10(6):1051-7.
  143. Rosano GM et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000 Dec;36(7):2154-9.
  144. Takahashi K et al. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod. 2000 May;15(5):1028-36.
  145. Nishibe A et al. [Effect of estriol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women]. Nippon Ronen Igakkai Zasshi. 1996 May;33(5):353-9.
  146. Kano H et al. Estriol retards and stabilizes atherosclerosis through an NO-mediated system. Life Sci. 2002 May 24;71(1):31-42.
  147. Atkinson C, Compston JE, et al. The effects of phytoestrogen isoflavones on bone density in women: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2004;79(2):326–33.
  148. Crisafulli A, Altavilla D, et al. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. J Clin Endocrinol Metab. 2004a;89(1):188–92.
  149. Crisafulli A, Marini H, et al. Effects of genistein on hot flushes in early postmenopausal women: A randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004b;11(4):400–4.
  150. Squadrito F, Altavilla D, et al. Effect of genistein on endothelial function in postmenopausal women: A randomized, double-blind, controlled study. Am J Med. 2003;114(6):470–6.